Xanthine oxidase inhibition for the treatment of stroke disease: A novel therapeutic approach

Expert Review of Cardiovascular Therapy

Volumn 9, Issue 4, 2011, Pages 399-401

  Higgins, Peter ^a   Ferguson, Lyn D ^a   Walters, Matthew R ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

allopurinol; cardiovascular; endothelium; oxidative stress; stroke; xanthine oxidase

Indexed keywords

ALLOPURINOL; FEBUXOSTAT; OXIPURINOL; URIC ACID; XANTHINE OXIDASE;

BLOOD VESSEL INJURY; CEREBROVASCULAR DISEASE; DRUG MEGADOSE; ENZYME ACTIVITY; ENZYME INHIBITION; HYPERURICEMIA; OXIDATIVE STRESS; REVIEW; STROKE;

HUMANS; STROKE; XANTHINE OXIDASE;

EID: 79955506523     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.11.29     Document Type: Review

References (14)

1. The European Stroke Organisation (ESO) Executive Committee and the ESCO Writing Committee. Guidelines for Management of Ischaemic Stroke and Transient Ischaemic Attack 2008. Cerebrovasc. Dis. 25, 457-507 (2008).
2. Higgins P, Dawson J, Walters M. The potential for xanthine oxidase inhibition in the prevention and treatment of cardiovascular and cerebrovascular disease. Cardiovasc. Psychiatry Neurol. 2009, 282059 (2009).
3. Dawson J, Walters M. Uric acid and xanthine oxidase: future therapeutic targets in the prevention of cardiovascular disease? Br. J. Clin. Pharmacol. 62(6), 633-644 (2006). (Pubitemid 44754682)
4. Noman A, Ang DS, Ogston S, Lang CC, Struthers AD. Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial. Lancet 375(9732), 2161-2167 (2010).
5. George J, Carr E, Davies J, Belch JF, Struthers A. High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation 114(23), 2508-2516 (2006). (Pubitemid 44901524)
6. Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA 300(8), 924-932 (2008).
7. Luk AJ, Levin GP, Moore EE, Zhou XH, Kestenbaum BR, Choi HK. Allopurinol and mortality in hyperuricaemic patients. Rheumatology 48, 804-806 (2009).
8. Hare JM, Mangal B, Brown J et al. Impact of oxypurinol in patients with symptomatic heart failure: results of the OPT-CHF study. J. Am. Coll. Cardiol. 51(24), 2301-2309 (2008). (Pubitemid 351783365)
9. Muir SW, Harrow C, Dawson J et al. Allopurinol use yields potentially beneficial effects on inflammatory indices in those with recent ischemic stroke: a randomized, double-blind, placebo-controlled trial. Stroke 39(12), 3303-3307 (2008).
10. Khan F, George J, Wong K, McSwiggan S, Struthers AD, Belch JF. Allopurinol treatment reduces arterial wave reflection in stroke survivors. Cardiovasc. Ther. 26(4), 247-252 (2008).
11. Dawson J, Quinn T, Harrow C et al. Allopurinol and nitric oxide activity in the cerebral circulation of those with diabetes. Diabetes Care 32(1), 135-137 (2009).
12. Dawson J, Quinn TJ, Harrow C, Lees KR, Walters MR. The effect of allopurinol on the cerebral vasculature of patients with subcortical stroke; a randomized trial. Br. J. Clin. Pharmacol. 68(5), 662-668 (2009).
13. Amaro S, Urra X, Gómez-Choco M et al. Uric acid levels are relevant in patients with stroke treated with thrombolysis. Stroke. 42(Suppl. 1), S28-S32 (2011).
14. Amaro S, Planas AM, Chamorro A. Uric acid administration in patients with acute stroke: a novel approach to neuroprotection. Expert Rev. Neurother. 8(2), 259-270 (2008). (Pubitemid 351281113)